ClinicalTrials.gg
RecruitingNCT07021794MonoclonalUpdated Sep 29, 2026

SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

A Phase 2 interventional study of Placebo and Sipavibart in Post-COVID / Long-COVID, sponsored by Nancy Klimas. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Nancy Klimas · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Sep 29, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States — 63 open to participants now, 85 under way, 7 of them phase 3. Post-Acute COVID-19 Syndrome · United States.

Planned enrollment
52nd of 156
100 · median 53
Started
2025
with 28 others
Phase 2
48 of 195
11 open now
Primary completion
2027-09
later than 54 of 84 live
Registered
155th of 195
by date

Among the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, this one is the 52nd largest by planned enrollment of the 156 interventional ones that give a count, is one of 29 that started in 2025, is one of 48 in phase 2, reaches primary completion later than 54 of the 84 other live ones, and was the 155th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

63 of the 195 studies in Post-Acute COVID-19 Syndrome with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 195 studies in Post-Acute COVID-19 Syndrome with a site in United States, or all of them as a file.
02

Study summary

This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.

Read the detailed description

Acute COVID-19 infection can present differently among infected patients, with the infection ranging in symptom presentation from asymptomatic and mild symptomatology to severe illness. Common symptoms tied to a COVID-19 infection include fever, chills, cough, respiratory ailments (shortness of breath or difficulty breathing), fatigue, muscle and/or joint pain, headache, loss of taste or smell, sore throat, congestion, and/or gastrointestinal (GI) disturbances (nausea, vomiting, and/or diarrhea). In some patients, these symptoms are short-lived and span the length of the acute infection, while in many patients the symptoms can linger for an extended period. Early indications point to inflammation playing a key role in acute COVID-19 illness and severity, and may play a role in prolonged Long COVID(LC) symptom intolerance and long-term sequelae. Researchers have demonstrated the involvement of persistent inflammation, poor antiviral responses, and evidence of chronic viral reactivation.

More recently, studies have demonstrated that mAb targeting the spike (S) protein of the SARS-CoV-2 may not only be effective in treating acute COVID-19 infection, especially variants prior to Omicron (alpha, beta, and delta), but also may play a role in addressing Long COVID. This implies that mAb infusions likely target SARS-CoV-2, decreasing activity, and potentially addressing disease pathogenesis tied to its activation, shutting down negative implications of inflammation tied to viral activation. This study will employ a two-arm randomized design to evaluate the efficacy of the drug Sipavibart in individuals experiencing LC symptoms. Participants will undergo six months of follow up after receiving either one dose of Sipavibart or one dose of placebo. After completion of the 6-month follow up, an open-label extension phase will be added at month 6 (week 24), where subjects who continue to experience symptoms of long COVID (regardless of the blinded treatment assignment) could be eligible to receive one dose of Sipavibart in an open-label fashion.

03

Conditions studied

  • Post-COVID / Long-COVID

Keywords

  • LongCOVID
  • Monoclonal antibody (mAb) therapy
  • Post-viral conditions
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

An individual is eligible for inclusion if all of the following apply:

  1. 18 to 70 years old,
  2. Inciting event: Acute COVID documented by testing (PCR or antigen testing in a clinical setting).
  3. Onset of COVID symptoms occurring on or prior to August 31st, 2023; and persistence of symptomatic expression of Long COVID (defined #6 below) for more than 3 months after COVID diagnosis.
  4. Current symptomatic expression meets the case definition of ME/CFS.
  5. PROMIS 29 score at screening of moderate to severe (≥60).
  6. Meets National Academy of Sciences (NAS) criteria for Long COVID with the following provisions:

    1. Allowance for normal illnesses of aging, such as hypertension and diabetes, if the conditions are treated and are in demonstrable stable and acceptable ranges at the time of screening and assessment. Specifically, blood pressures \< 150 systolic and 90 diastolic mmHg are required.
    2. Allowance of stable comorbid conditions common in post viral illness, such as fibromyalgia, irritable bowel, interstitial cystitis, dysautonomia that have not required hospitalization in the two years prior to recruitment.
  7. Able to provide written consent to study. Agrees to participate in follow-up visits.

Subject Exclusion Criteria

An individual is ineligible to participate if any of the following apply:

  1. Known active acute SARS-CoV-2 infection ≤ 4 weeks from consent.
  2. Known severe anemia, defined as \< 8 g/dL.
  3. Known stroke that resulted in cognitive impairment within 3 months of enrollment.
  4. Self-report of current treated or untreated major depression with psychotic or melancholic features, schizophrenia, bipolar disorder, delusional disorders, dementias of any type, or a history of CNS disorders that may affect cognitive function (i.e., epilepsy, stroke, brain tumor, multiple sclerosis, Parkinson's Disease, Alzheimer's disease), or substance abuse during the last two years, excluding cannabis products.
  5. Allergy to any ingredient of the study drug (self-report)

    1. Sipavibart is supplied as 150 mg/mL of active ingredient in 20 mM L-histidine/L-histidine hydrochloride, 220 mM L-arginine hydrochloride, and 0.04% (w/v) polysorbate 80, at pH 6.0.
    2. to other humanized mAbs.
  6. Current heavy alcohol or tobacco use (self-report). Alcohol consumption not to exceed approximately 15 drinks per week (with a drink defined as 12 oz beer, 5 oz wine, or 1.5 oz distilled spirits) and tobacco use not to exceed 20 cigarettes (or equivalent) per day during the last month.
  7. Active chronic infections such as , Virus (HBV), and Virus (HCV), indicated by self-report, and abnormal liver function tests (>3x ) or evidence in the health record of chronic active hepatitis or human immunodeficiency virus (HIV).
  8. Renal disease (self-report; laboratory results: renal insufficiency with serum creatinine > 2.0 mg/dL or \< 44; or currently on renal dialysis)
  9. Liver disease (self-report or laboratory results: hepatic insufficiency ( >2.5mg/dL or transaminases > 3X the upper limits of normal)
  10. Uncontrolled diabetes, evidenced by combination of morning blood glucose and previous diagnosis of diabetes, AIC>7
  11. Diagnosed with congestive heart failure or significant arrythmia (ventricular tachycardia with a rapid rate at rest (> 100 bpm), persistent atrial fibrillation, or second- or third-degree heart block)
  12. Pre-existing sustained severe hypertension (BP >180/110 mmHg in the sitting position)
  13. Any of the following within 4 weeks of consent (Self-reported/medical record):

    1. an acute myocardial infarction or unstable angina
    2. uncontrolled arrhythmias causing symptoms or hemodynamic compromise
    3. acute myocarditis or pericarditis, uncontrolled acutely decompensated heart failure (acute pulmonary edema)
    4. acute pulmonary embolism
    5. suspected dissecting aneurysm
    6. severe hypoxemia at rest
    7. any acute or chronic disorder that may affect exercise performance, or
    8. if they are aggravated by exercise (e.g., infection, thyrotoxicosis, unable to cooperate)
  14. Diagnosed bleeding disorders or use of blood-thinning medications.
  15. Current or previous receipt of any COVID antiviral medication within 30 days prior to screening (self reported)
  16. Currently have exclusionary diagnoses that could reasonably explain the symptoms of their fatiguing illness and their severity, using the exclusion criteria best described in the Ambiguities in case definition paper for CFS, as described in detail in [13] which clarifies exclusionary conditions. These exclusionary diagnoses that are not otherwise listed above comprise:

    1. Organ failure
    2. Chronic inflammatory diseases
    3. Major neurologic diseases that could cause fatigue or neurologic deficits
    4. Diseases requiring systemic treatment (i.e., transplantation, chemotherapy, radiation)
    5. Major endocrine diseases
    6. Untreated primary sleep disorders
    7. > 40 kg/m2
    8. Temporary conditions discovered at screening, such as

      • Temporary effects of medications
      • Temporary sleep deprivation
      • Untreated hypothyroidism, hypothyroidism that has been inadequately controlled during the last 3 months, or free T4 level not within normal limits
      • Active infection (for COVID-19 infection and other infections, participants may be rescreened six weeks after resolution of infection)
  17. Known diagnosis of chronic Lyme disease with persistent symptoms, sequelae, or related therapy.
  18. Any marijuana illicit drug use within 30 days of
  19. Inability to discontinue symptomatic medications for the identified time periods
  20. Moderate or severe patients, such as those described in the NIH COVID-Treatment Guidelines
  21. Are scheduled for a surgery during the period of study participation, had minor surgery within three months prior to screening, or had major surgery within 6 months prior to screening
  22. Participating in any interventional (including social-behavioral therapy) clinical trial of an therapy within 6 weeks prior to consent, or planning to participate in another interventional clinical trial of an investigational therapy during the course of this study
  23. COVID Vaccination within 90 days prior to entry and for the duration of the study
  24. Pregnancy is excluded. Women of childbearing age will be given a pregnancy test.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Sipavibart

    Participants receive a single intramuscular dose of Sipavibart, 300 mg intramuscular and are then followed for a duration of six months.

    Drug: Placebo

  • Placebo comparator
    Placebo

    Participants receive single dose of placebo (saline) indistinguishable from the active drug in appearance, and are then followed for a duration of six months.

    Biological: Sipavibart

Interventions

  • DrugPlacebo

    A single dose of placebo (saline) indistinguishable from the active drug in appearance

  • BiologicalSipavibart

    A single intramuscular dose of Sipavibart, 300 mg

06

What researchers measure

Primary outcomes

  1. Patient-Reported Outcomes Measurement Information System-29

    Comprehensive Symptom Burden Index (CSBI) total scores will serve as a composite outcome measure derived from eight PROMIS domains to capture overall symptom burden. Scores will be calculated at baseline and Week 12. Efficacy will be determined by the proportion of participants classified as IMPROVED, defined as having a ≥4.5-point increase in CSBI from baseline, a threshold representing moderate and clinically meaningful improvement.

    Time frame: 12 weeks

  2. Review of Treatment Related Adverse Events

    Number of participants with treatment-related adverse events as assessed by frequency of safety events during the study period.

    Time frame: 24 weeks

Secondary outcomes

  1. Symptom-specific participant-reported outcome measures

    Evaluate change in Comprehensive Symptom Burden Index (CSBI) score from baseline to Week 24 between Sipavibart and placebo groups.

    Time frame: 24 weeks

  2. Change in Simple Reaction Time (Milliseconds)

    Change in raw Simple Reaction Time, measured in milliseconds using the CNS Vital Signs computerized test battery, from baseline to Weeks 12 and 24.

    Time frame: Baseline, 12 and 24 weeks

  3. Self-reported fatigue using MFI

    Change in Multidimensional Fatigue Inventory (MFI) total and subscale scores (General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Activity, Reduced Motivation) from baseline to Weeks 12 and 24. Correlation of MFI scores with PROMIS Fatigue and DSQ-PEM subscales (convergent validity).

    Time frame: 12 and 24 weeks

  4. Change in Heart Rate Post-6MWT

    Change in Heart Rate post 6-minute walk distance (6MWT), in meters, from baseline to Weeks 12 and 24.Unit: Beats per minute (bpm)

    Time frame: 12 and 24 weeks

  5. Processing Speed

    Change in Processing Speed score (Standard score or percentile) from baseline to Weeks 12 and 24 as measured by CNS Vital Signs.

    Time frame: 12 and 24 weeks

  6. Attention

    Change in Attention (Standard Score) from baseline to Weeks 12 and 24 as measured by CNS Vital Signs.

    Time frame: Baseline, 12 and 24 weeks

  7. Systolic Blood Pressure Response During NASA Lean Test

    Change in systolic blood pressure (mmHg) from baseline to 10 minutes upright during the NASA Lean Test

    Time frame: Baseline, 12 and 24 Weeks

  8. Diastolic Blood Pressure Response During NASA Lean Test

    Change in diastolic blood pressure (mmHg) from baseline to 10 minutes upright during the NASA Lean Test

    Time frame: Baseline, 12 and 24 Weeks

  9. Symptom Score During NASA Lean Test

    Change in self-reported orthostatic intolerance symptom score, measured using a 0-10 numeric scale, during the NASA 10-minute Lean Test

    Time frame: Baseline, 12 and 24 weeks

  10. Within-participant change in PROMIS Fatigue scores from baseline to Week 24

    PROMIS Fatigue domain score measured at baseline, Week 12, and Week 24 to assess change over time.

    Time frame: Baseline, 12 weeks, 24 weeks

  11. Within-participant change in PROMIS Pain Interference scores

    PROMIS Pain Interference domain score measured at baseline, Week 12, and Week 24 to assess change over time.

    Time frame: Baseline, 12 weeks, 24 weeks

  12. Within-participant change in PROMIS Physical Function scores

    PROMIS Physical Function domain score measured at baseline, Week 12, and Week 24 to assess change over time.

    Time frame: Baseline, 12 weeks, 24 weeks

  13. Change in PROMIS Cognitive Function 8a T-score

    Evaluates cognitive function using PROMIS Cognitive Function 8a at baseline, Week 12, and Week 24. Used to assess differential treatment effects by baseline symptom cluster (Cognitive Dysfunction group).

    Time frame: Baseline, 12 Week, 24 week

  14. Change in Orthostatic Hypotension Questionnaire (OHQ) composite score

    Evaluates autonomic dysfunction using the OHQ at baseline, Week 12, and Week 24. Used to assess differential treatment effects by baseline symptom cluster (Autonomic Dysfunction group).

    Time frame: Baseline, 12 weeks, 24 weeks

  15. Change in DePaul Symptom Questionnaire-Post-Exertional Malaise (DSQ-PEM)

    Evaluates post-exertional malaise and exercise intolerance using the DSQ-PEM T score at baseline, Week 12, and Week 24. Used to assess differential treatment effects by baseline symptom cluster .

    Time frame: Baseline, 12 weeks, 24 weeks

  16. Change in DePaul Symptom Questionnaire (DSQ) score

    Assesses symptom burden using the DSQ at baseline, Week 12, and Week 24.

    Time frame: Baseline, 12 weeks, 24 weeks

  17. Change in Pittsburgh Sleep Quality Index (PSQI) global score

    Assesses sleep quality using the PSQI at baseline, Week 12, and Week 24. Scores (0-21)

    Time frame: Baseline, 12 weeks, 24 weeks

  18. Change in Brief Pain Inventory (BPI) severity score

    Assesses pain severity using the BPI at baseline, Week 12, and Week 24. Scores (1-10).

    Time frame: Baseline, 12 weeks, 24 weeks

  19. Change in Modified Medical Research Council (mMRC) Dyspnea Scale score

    Assesses dyspnea using the mMRC scale at baseline, Week 12, and Week 24. Score range 0-4

    Time frame: Baseline, 12 weeks, 24 weeks

  20. Change in Generalized Anxiety Disorder-7 (GAD-7) score

    Assesses anxiety symptoms using the GAD-7 at baseline, Week 12, and Week 24. Score range 0-21

    Time frame: Baseline, 12 weeks, 24 weeks

  21. Change in Patient Health Questionnaire-8 (PHQ-8) score

    Assesses depressive symptoms using the PHQ-8 at baseline, Week 12, and Week 24. Score range 0-24

    Time frame: Baseline, 12 weeks, 24 weeks

  22. Change in Brief Illness Perception Questionnaire (B-IPQ) total score

    Assesses illness perception using the B-IPQ at baseline, Week 12, and Week 24. Score range 0-80

    Time frame: Baseline, 12 weeks, 24 weeks

  23. Change in Functional Capacity Scale (FUNCAP) score

    Assesses functional impairment using the FUNCAP scale at baseline, Week 12, and Week 24. Score range 0-100

    Time frame: Baseline, 12 weeks, 24 weeks.

  24. Change in Composite Symptom Burden Index (CSBI) score

    The CSBI is a derived score summarizing symptom burden across multiple validated domains (e.g., fatigue, pain, sleep, mood, cognitive function). Domain scores are standardized and averaged to produce a single CSBI value per participant. Paired differences from baseline to Week 12 and Week 24 will be analyzed to assess intra-individual changes and overall cohort-level trends.

    Time frame: Baseline, 12 weeks, 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Nova Southeastern University
    Fort Lauderdale, Florida 33314, United States
    Recruiting
    • Alejandro Montealegre, APRN · Contactam3841@nova.edu · 954-262-2286
    • Korrine Rodrigue, PhD · Contactkr1686@nova.edu · 802-779-8122
    • Amanpreet Cheema, PhD · Sub investigator
    • Kristina Aenlle, PhD · Sub investigator
    • David Quesada, PhD · Sub investigator
    • Irma Rey, MD · Sub investigator
08

References and documents

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Sep 2027, 26 months after the start.

Of 46 non-industry phase 2 interventional studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 24. This study's planned 26 months is above that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: start Jun 2025 → Jul 2025, primary completion Dec 2026 → Sep 2027 and completion Dec 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Jun 15, 2025
StartActual
Jul 28, 2025was Jun 2025
Primary completionEst.
Sep 30, 2027was Dec 2026
CompletionEst.
Sep 30, 2027was Dec 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 16, 2025→Jul 28, 2025
Sep 29, 2026
Primary completion
Dec 31, 2026→Sep 30, 2027
Sep 29, 2026
Study completion
Dec 31, 2026→Sep 30, 2027
Sep 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Nova Southeastern University · Fort Lauderdale, United StatesContact m•••@nova.edu · •••2286→a•••@nova.edu · •••2286Contact f•••@nova.edu→k•••@nova.edu · •••8122
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Start date Jun 16, 2025→Jul 28, 2025
    Primary completion Dec 31, 2026→Sep 30, 2027
    Study completion Dec 31, 2026→Sep 30, 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Nova Southeastern University · Fort Lauderdale, United StatesContact m•••@nova.edu · •••2286→a•••@nova.edu · •••2286Contact f•••@nova.edu→k•••@nova.edu · •••8122
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07021794
Lead sponsor
Nancy Klimas
Collaborators
Florida Department of Health
Responsible party
Nancy Klimas (Director, Institute for Neuro Immune Medicine, Nova Southeastern University) — Sponsor-investigator
First posted
Jun 15, 2025
Start date
Jul 28, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Nancy Klimas, MD
Contact
nklimas@nova.edu
954-262-2286
Alejandro Montealegre, MSN, ARNP
Contact
am3841@nova.edu
954-262-2286
Nancy Klimas, MD
principal investigator · Nova Southeastern University
Korrine Rodrigue, PhD
study director · Nova Southeastern University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion